In this episode of Medsider Radio, we had a fun chat with Trent Reutiman, CEO of Mercator MedSystems. Trent and his team have developed microinfusion devices with the unique ability to locally and directly deliver targeted therapeutics during catheter-based interventions where mechanical therapy isn’t sufficient.
 
Trent has 25 years of leadership experience in medtech including roles in sales, marketing, and business management with a focus on minimally invasive interventional products for companies like IDEV, ROX Medical, RITA Medical Systems, Guidant, and Cordis.

In this interview, Trent talks about the importance of generating data, how to balance commercial efforts with clinical initiatives, and why meticulous management is critical for successful commercialization. 

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Trent Reutiman.